CMB International Global Markets | Equity Research | Company Update

GAC Group (2238 HK)

Homegrown brands likely to narrow loss in 2H23

Maintain BUY. GAC probably faces a mixed picture in 2H23 after an in-line 2Q23, as we are concerned about GAC Mitsubishi's goodwill impairment. On the other hand, we expect Aion to cut loss significantly in 2H23E and FY24E. We now value Aion at HK\$ 62bn, based on 0.7x our FY24E P/S. We believe more investors would pay attention to Aion, should its margins improve gradually.

- 2Q23 net profit in line. GAC's 2Q23 revenue was 9% lower than our prior forecast due to lower average selling prices amid price war. Its gross margin of 4.1% was in line with our estimates. Its equity income from joint ventures (JVs) and associates of RMB 2.4bn in 2Q23 was RMB 300mn lower than our prior forecast. Its net profit of RMB 1.4bn in 2Q23 was only RMB 3mn higher than our prior forecast, as SG&A, R&D expenses and interest income beat.
- Mixed picture in 2H23E. Trumpchi continued to make profit in 1H23 with GPM rising YoY even amid price war and Aion made profit in Jun 2023. Therefore, we raise our FY23E GP forecast by 11%. On the other hand, profitability at GAC Honda and GAC Mitsubishi missed in 1H23, and we cut FY23E equity income by 11% to RMB 9.4bn. We are also concerned about possible goodwill impairment at GAC Mitsubishi, as it has already halted production. We factor in an impairment loss of RMB 1.3bn in 2H23E. Therefore, we lower our FY23E net profit by RMB 700mn to RMB 4.9bn.
- A better FY24E ahead. We expect Aion to cut net loss by more than half YoY in FY24E, as the Hyper series ramps up. We also project Trumpchi (excluding GAC Research Institute) to continue making profit in FY24E, although a decline from this year, as more PHEVs are to be on sale. In addition, GAC Mitsubishi's overhang is likely to be gone in FY24E, leading to a smaller decline for GAC's equity income. We project FY24E net profit to rise 20% YoY.
- Valuation/Key risks. We use sum-of-the-parts (SOTP) valuation to factor in Aion's planned spin-off. We value Aion HK\$ 4.4 per share, based on 0.7x (unchanged) our revised FY24E P/S. We value HK\$ 2.6 per share for JVs and associates based on 3.0x (unchanged) our FY24E P/E, which is equivalent to a conservative dividend discount model assuming equity income to decline YoY significantly from FY25E and become 0 in FY29E. We value 0 for all other businesses combined. Accordingly, we maintain BUY rating and target price of HK\$ 7.00. Key risks to our rating and target price include lower sales volume and margins especially for Aion and a sector de-rating.

Earnings Summary

(YE 31 Dec)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue (RMB mn)	75,676	110,006	142,585	156,375	170,166
YoY growth (%)	19.8	45.4	29.6	9.7	8.8
Net income (RMB mn)	7,511	7,983	4,924	5,907	7,593
EPS (RMB)	0.73	0.77	0.47	0.56	0.72
YoY growth (%)	25.9	6.3	(38.3)	20.0	28.5
P/E (x)	5.2	5.1	9.0	7.5	5.9
P/B (x)	0.4	0.4	0.4	0.4	0.4
Yield (%)	3.6	4.2	2.2	2.7	3.4
ROE (%)	8.6	7.8	4.3	5.0	6.1
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIGM estimates



BUY (Maintain)

Target Price	HK\$ 7.00
(Previous TP	HK\$ 7.00)
Up/Downside	+69.9%
Current Price	HK\$ 4.12

China Auto Sector

SHI Ji, CFA (852) 3761 8728 shiji@cmbi.com.hk

DOU Wenjing, CFA (852) 6939 4751 douwenjing@cmbi.com.hk

GU Sijie

jasongu@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	43,200
Avg 3 mths t/o (HK\$ mn)	65
52w High/Low (HK\$)	6.81/4.05
Total Issued Shares (mn)	10,485
Source: Bloomberg	

Shareholding Structure

Guangzhou Automobile	52.5%
Industry	52.570
Others	47.5%
Source: HKEx	

Share Performance

	Absolute	Relative
1-mth	-11.6%	-4.0%
3-mth	-5.9%	-1.7%
6-mth	-17.3%	-7.1%
Source: Bloomberg	1	

12-mth Price Performance



Source: Bloomberg

Auditor: PricewaterhouseCoopers

Related Reports

"GAC Group – 2Q23E NP to fall QoQ; Hyper margin key in 2H23" – 3 Jul 2023



Figure 1: Quarterly results

RMB mn	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	YoY	QoQ
Sales volume (units)	608,167	541,759	675,024	608,761	539,875	623,029	15.0%	15.4%
Revenue	23,268	25,421	31,678	29,639	26,557	35,354	39.1%	33.1%
Gross profit	1,025	1,160	1,470	2,320	610	1,458	25.7%	139.1%
R&D expenses	(241)	(319)	(388)	(760)	(397)	(464)	45.6%	16.8%
SG&A expenses	(2,110)	(2,287)	(2,324)	(1,676)	(1,883)	(2,528)	10.6%	34.3%
Investment Income	4,227	4,271	3,770	2,049	2,955	2,494	-41.6%	-15.6%
Operating profit	2,854	2,883	2,102	(383)	1,145	1,241	-57.0%	8.4%
Net profit	3,009	2,742	2,312	6	1,538	1,428	-47.9%	-7.1%
Gross margin	4.4%	4.6%	4.6%	7.8%	2.3%	4.1%	-0.4 ppt	1.8 ppt
Operating margin	12.3%	11.3%	6.6%	-1.3%	4.3%	3.5%	-7.8 ppt	-0.8 ppt
Net margin	12.9%	10.8%	7.3%	0.0%	5.8%	4.0%	-6.7 ppt	-1.8 ppt

Source: Company data, CMBIGM

Figure 2: Earnings revision

		New			Old			Diff (%)	
RMB mn	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	142,585	156,375	170,166	137,042	145,964	155,076	4.0%	7.1%	9.7%
Gross profit	6,242	8,509	13,603	5,615	9,110	14,183	11.2%	-6.6%	-4.1%
Operating profit	(5,666)	(3,135)	592	(5,773)	(3,234)	504	N/A	N/A	17.5%
Net profit	4,924	5,907	7,593	5,612	6,259	8,015	-12.3%	-5.6%	-5.3%
Gross margin	4.4%	5.4%	8.0%	4.1%	6.2%	9.1%	0.3 ppt	-0.8 ppt	-1.2 ppt
Operating margin	-4.0%	-2.0%	0.3%	-4.2%	-2.2%	0.3%	0.2 ppt	0.2 ppt	0.0 ppt
Net margin	3.5%	3.8%	4.5%	4.1%	4.3%	5.2%	-0.6 ppt	-0.5 ppt	-0.7 ppt

Source: CMBIGM estimates

Figure 3: CMBI estimates vs consensus

		CMBIGM			Consensus	;		Diff (%)	
RMB mn	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	142,585	156,375	170,166	131,369	146,434	161,940	8.5%	6.8%	5.1%
Gross profit	6,242	8,509	13,603	8,594	11,145	13,946	-27.4%	-23.7%	-2.5%
Operating profit	(5,666)	(3,135)	592	(5,239)	(4,498)	(1,224)	N/A	N/A	N/A
Net profit	4,924	5,907	7,593	8,144	8,623	9,488	-39.5%	-31.5%	-20.0%
Gross margin	4.4%	5.4%	8.0%	6.5%	7.6%	8.6%	-2.2 ppt	-2.2 ppt	-0.6 ppt
Operating margin	-4.0%	-2.0%	0.3%	-4.0%	-3.1%	-0.8%	0.0 ppt	1.1 ppt	1.1 ppt
Net margin	3.5%	3.8%	4.5%	6.2%	5.9%	5.9%	-2.7 ppt	-2.1 ppt	-1.4 ppt

Source: Bloomberg, CMBIGM estimates

Figure 4: SOTP valuation

GAC (2238 HK)	FY24E (RMB bn)	Target P/E Multiple	Target P/S Multiple	Est. Shareholding	Target Market Cap (HK\$ bn)	Target Price (HK\$)
Estimated Revenue of Aion	82.2	-	0.7x	75%	46.6	4.4
Estimated Share of Profits of Joint Ventures & Associates	8.5	3.0x	-	-	27.4	2.6
SOTP					74.0	7.0

Source: CMBIGM estimates



Financial Summary

Income statement						Cash flow					
YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E	YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue	75,676	110,006	142,585	156,375	170,166	Profit before taxation	7,412	7,377	3,955	5,505	7,943
Cost of sales	(71,777)	(105,550)	(136,344)	(147,866)	(156,563)	Depreciation/amortization	5,719	6,690	7,547	8,500	9,467
Gross profit	3,899	4,457	6,242	8,509	13,603	Change in working capital	(8,134)	(9,458)	(2,274)	794	(1,991)
						Others	(11,488)	(11,246)	(7,908)	(6,871)	(6,005)
Selling exp.	(4,340)	(4,228)	(4,928)	(5,326)	(5,722)	Net cash from operating	(6,491)	(6,638)	1,320	7,929	9,414
Admin exp.	(4,556)	(5,487)	(6,529)	(7,251)	(8,023)						
Other gains	1,371	(1,409)	(450)	933	733	Capex	(6,243)	(8,014)	(9,000)	(9,100)	(9,100)
Operating profit	(3,626)	(6,668)	(5,666)	(3,135)	592	Others	13,478	6,421	8,556	6,617	4,673
						Net cash from investing	7,235	(1,592)	(444)	(2,483)	(4,427)
Net finance costs	(367)	(21)	243	171	188						
Profit share of asso.&JVs	11,404	14,065	9,378	8,468	7,163	Net borrowings	2,657	6,200	(6,827)	(505)	(2,685)
Pre-tax profit	7,412	7,377	3,955	5,505	7,943	Dividend paid	(2,135)	(2,485)	(2,341)	(1,682)	(2,042)
						Others	255	21,466	(268)	(261)	(254)
Тах	154	536	434	237	(62)	Net cash from financing	777	25,181	(9,435)	(2,449)	(4,980)
Minority interests	(55)	71	535	165	(287)						
Net profit	7,511	7,983	4,924	5,907	7,593	Net change in cash	1,520	16,950	(8,560)	2,997	7
						Cash at year beginning	15,791	17,235	34,222	25,662	28,659
						Exchange difference	(76)	37	-	-	-
						Cash at year end	17,235	34,222	25,662	28,659	28,666
							,	,	,	,	,

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E	YE 31 Dec	FY21A	FY22A	FY23E	FY24E	FY25E
Current assets	61,192	91,792	99,140	107,744	113,049	Sales mix (%)					
Cash & equivalents	17,235	34,222	25,662	28,659	28,666	Automobile	65.0	71.5	76.9	79.6	81.3
Account receivables	25,110	31,597	44,924	49,269	53,614	Parts and services	32.1	25.2	20.5	17.8	16.3
Inventories	8,111	12,362	14,942	16,205	17,158	Finance and others	2.9	3.2	2.6	2.5	2.4
Other current assets	10,736	13,612	13,612	13,612	13,612						
						Growth (%)					
Non-current assets	93,059	98,283	100,354	102,195	103,791	Revenue	19.8	45.4	29.6	9.7	8.8
PP&E	19,476	20,761	19,645	18,502	17,262	Gross profit	69.8	14.3	40.1	36.3	59.9
Intangibles	13,581	14,471	16,379	17,257	17,451	Operating profit	1.6	83.9	(15.0)	(44.7)	(118.9)
Deferred income tax	2,834	3,715	3,715	3,715	3,715	Net profit	25.9	6.3	(38.3)	20.0	28.5
Other non-current assets	57,168	59,335	60,614	62,721	65,363						
Total assets	154,251	190,075	199,493	209,939	216,841	Profit & loss ratio (%)					
						Gross margin	5.2	4.1	4.4	5.4	8.0
Current liabilities	49,133	56,688	64,267	69,858	70,391	Operating margin	(4.8)	(6.1)	(4.0)	(2.0)	0.3
Bank borrowings	9,889	13,813	7,416	6,222	3,038	Net profit margin	9.9	7.3	3.5	3.8	4.5
Account payables	38,490	42,069	56,032	62,792	66,486						
Tax payable	202	185	185	185	185	Balance sheet ratio					
Other current liabilities	551	622	635	658	683	Net cash/total equity (x)	0.1	0.1	0.1	0.2	0.2
						Current ratio (x)	1.2	1.6	1.5	1.5	1.6
Non-current liabilities	12,469	11,084	10,075	10,582	11,111	Receivable turnover days	121	105	115	115	115
Bank borrowings	7,527	5,697	4,697	5,197	5,697	Inventory turnover days	41	43	40	40	40
Government Grants	2,196	2,183	2,056	1,947	1,855	Payable turnover days	196	145	150	155	155
Other non-current liabilities	2,747	3,204	3,323	3,438	3,559						
Total liabilities	61,602	67,772	74,343	80,440	81,503	Profitability (%)					
						ROE	8.6	7.8	4.3	5.0	6.1
Share capital	10,371	10,487	10,518	10,528	10,528	ROA	5.1	4.6	2.5	2.9	3.6
Reserves	79,943	102,802	106,224	110,808	116,439						
Non-controlling interests	2,335	9,014	8,408	8,163	8,371	Per share data (RMB)					
Shareholders' equity	90,313	113,289	116,742	121,336	126,967	EPS	0.73	0.77	0.47	0.56	0.72
Total equity and liabilities	154,251	190,075	199,493	209,939	216,841	DPS	0.22	0.24	0.15	0.17	0.22
						-					

Source: Company data, CMBIGM estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore, to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.